At an event follow-up of 377 years ( IQR 350-422 ) , 3-year event-free survival was 78 % ( 95 % CI 70-84 ) in the lapatinib group , 76 % ( 68-82 ) in the trastuzumab group , and 84 % ( 77-89 ) in the combination group .